Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ambroxol in Type III Gaucher Disease (GD3): A Prospective 6-Month Single-Center Open-Label Study With an Optional 12-month Extension Phase

NCT07285369 is registered in ClinicalTrials.gov with Agyany Pharma LTD as lead sponsor.

NCT NCT07285369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ambroxol in Type III Gaucher Disease (GD3): A Prospective 6-Month Single-Center Open-Label Study With an Optional 12-month Extension Phase
Lead sponsor
Agyany Pharma LTD
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2025
Completion date
March 30, 2026
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 3